Re-Vana Therapeutics closed a Series A round with $11.9 million in funding, an oversubscription of $4 million, according to a press release.
The funding will be used to advance the development of the company’s photo-cross-linked biodegradable drug delivery technologies, EyeLief, EyeLief-SD and OcuLief, and expand the company’s operations and development teams.
Visionary Ventures led the financing, and additional investors included ExSight Ventures, InFocus Capital Partners and existing U.K. investors Qubis Ltd, Co-Fund NI and Techstart Ventures.
According to the release, nonclinical